➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
McKesson
Baxter
Boehringer Ingelheim
Moodys

Last Updated: October 24, 2021

DrugPatentWatch Database Preview

PENTASA Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Pentasa patents expire, and when can generic versions of Pentasa launch?

Pentasa is a drug marketed by Takeda Pharms Usa and is included in one NDA.

The generic ingredient in PENTASA is mesalamine. There are twenty-eight drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the mesalamine profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Pentasa

A generic version of PENTASA was approved as mesalamine by PADAGIS ISRAEL on September 17th, 2004.

  Free Forever Trial

Drug patent expirations by year for PENTASA
Drug Prices for PENTASA

See drug prices for PENTASA

Drug Sales Revenue Trends for PENTASA

See drug sales revenues for PENTASA

Recent Clinical Trials for PENTASA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
AIDS Healthcare FoundationPhase 1/Phase 2
HIV Immunotherapeutics InstitutePhase 1/Phase 2
Xijing Hospital of Digestive DiseasesPhase 3

See all PENTASA clinical trials

Pharmacology for PENTASA
Drug ClassAminosalicylate

US Patents and Regulatory Information for PENTASA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms Usa PENTASA mesalamine CAPSULE, EXTENDED RELEASE;ORAL 020049-001 May 10, 1993 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
Takeda Pharms Usa PENTASA mesalamine CAPSULE, EXTENDED RELEASE;ORAL 020049-002 Jul 8, 2004 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for PENTASA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms Usa PENTASA mesalamine CAPSULE, EXTENDED RELEASE;ORAL 020049-001 May 10, 1993 ⤷  Free Forever Trial ⤷  Free Forever Trial
Takeda Pharms Usa PENTASA mesalamine CAPSULE, EXTENDED RELEASE;ORAL 020049-001 May 10, 1993 ⤷  Free Forever Trial ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School
McKesson
Baxter
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.